首页> 外国专利> Binding of E-selectin or P-selectin to sialyl Lewis.sup.x or sialyl-Lewis. sup.a

Binding of E-selectin or P-selectin to sialyl Lewis.sup.x or sialyl-Lewis. sup.a

机译:E-选择蛋白或P-选择蛋白与唾液酸化Lewis.x或唾液酸化-路易斯的结合。速霸

摘要

This invention relates to compounds that inhibit the binding of E-selectin and/or P-selectin to sialyl-Lewisx or sialyl-Lewisa presented on a cell surface having the general structure IMAGE wherein X is selected from the group consisting of -(CH2)nCO2H, -O(CH2)mCO2H, -(CH2)nO(CH2)mCO2H, -CONH(CH2)mCO2H, -CH(OZ)(CO2H), -CH(Z)(CO2H), -(CH2)nSO3H, -(CH2)nPO3D1D2, -NH(CH2)mCO2H, -CONH(CHR6)CO2H, (1-H-tetrazolyl-5-alkyl-), and -OH; R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, halogen, -OZ, -NO2, -NH2 and -NHZ; R3 is selected from the group consisting of hydrogen, halogen, alkyl, -OZ and -NHZ; R4 is selected from the group consisting of hydrogen, halogen, alkyl, hydroxyl, hydroxyl-O-sulfate and -OZ; R5 is selected from the group consisting of hydroxyl, -CN, -N3, -NH2, -NHNH2, -NE1E2, -NHE1, -NHCO(CH2)nCO2H, -S(CH2)mCO2H and -NHCHNHNH2; R6 is selected from the group consisting of hydrogen, alkyl, aralkyl, hydroxyalkyl, aminoalkyl, alkyl carboxylic acid and alkyl carboxamide; wherein n is 0 to 6, m is 1 to 6, p is 0 to 6, b is 0 to 2, Z is alkyl, aryl or aralkyl, D1 and D2 are independantly hydrogen or alkyl, E1 is alkyl or -(CH2)8CO2H, and E2 is alkyl, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. This invention also relates to methods of inhibiting the binding of E-selectin and/or P-selectin to sialyl-Lewisx or sialyl-Lewisa presented on a cell surface using said compounds and to pharmaceutically active compositions comprising compounds that inhibit the binding of E-selectin to sialyl-Lewisx and to methods of treatment of septic shock, ARDS, Crohn's disease, chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis, and reperfusion injuries that occur following heart attacks, strokes and organ transplants.
机译:本发明涉及抑制E-选择蛋白和/或P-选择蛋白与存在于细胞表面的具有结构的唾液酸基-Lewisx或唾液酸基-Lewisa结合的化合物,其中X选自- CH2)nCO2H,-O(CH2)mCO2H,-(CH2)nO(CH2)mCO2H,-CONH(CH2)mCO2H,-CH(OZ)(CO2H),-CH(Z)(CO2H),-(CH2) nSO3H,-(CH2)nPO3D1D2,-NH(CH2)mCO2H,-CONH(CHR6)CO2H,(1-H-四唑基-5-烷基-)和-OH; R1和R2独立地选自氢,烷基,卤素,-OZ,-NO2,-NH2和-NHZ; R3选自氢,卤素,烷基,-OZ和-NHZ; R4选自氢,卤素,烷基,羟基,羟基-O-硫酸盐和-OZ; R5选自羟基,-CN,-N3,-NH2,-NHNH2,-NE1E2,-NHE1,-NHCO(CH2)nCO2H,-S(CH2)mCO2H和-NHCHNHNH2; R6选自氢,烷基,芳烷基,羟烷基,氨基烷基,烷基羧酸和烷基羧酰胺;其中n为0至6,m为1至6,p为0至6,b为0至2,Z为烷基,芳基或芳烷基,D1和D2独立地为氢或烷基,E1为烷基或-(CH2) 8CO 2 H和E 2是烷基,及其药学上可接受的盐,酯,酰胺和前药。本发明还涉及使用所述化合物抑制E-选择蛋白和/或P-选择蛋白与存在于细胞表面的唾液酸化-Lewisx或唾液酸化-Lewisa结合的方法,以及涉及包含抑制E-选择素和/或P-选择素结合的化合物的药物活性组合物。选择素可用于唾液酸化-刘易士(Sialyl-Lewisx)以及败血性休克,ARDS,克罗恩病,慢性炎症性疾病(如牛皮癣和类风湿性关节炎)以及心脏病发作,中风和器官移植后发生的再灌注损伤的治疗方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号